• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals Inc (NQ: CRNX )

    57.81 +0.99 (+1.74%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Crinetics Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 Next >
    Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
    U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
    Via Benzinga
    Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst
    Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating  
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
    Via Benzinga
    9 Analysts Have This to Say About Crinetics Pharmaceuticals
    Via Benzinga
    Analyst Expectations for Crinetics Pharmaceuticals's Future
    Via Benzinga
    Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics to Highlight Broad Pipeline at ENDO 2023
    Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Where Crinetics Pharmaceuticals Stands With Analysts
    Via Benzinga
    The Latest Analyst Ratings for Crinetics Pharmaceuticals
    Via Benzinga
    Crinetics Pharmaceuticals's Return On Capital Employed Overview
    Via Benzinga
    Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
    Via Benzinga
    Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Provides Update on CRN04777 Program
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
    Topline results for PATHFNDR-1 study expected in Q3 2023 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals's Return On Capital Employed Overview
    Benzinga Pro data, Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter. 
    Via Benzinga
    Crinetics Pharmaceuticals: Q2 Earnings Insights
      Crinetics Pharmaceuticals (NASDAQ:CRNX) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.